Motley Fool Wealth Management LLC Sells 7,785 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Motley Fool Wealth Management LLC reduced its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 3.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 212,218 shares of the company’s stock after selling 7,785 shares during the quarter. Motley Fool Wealth Management LLC owned approximately 0.36% of Inari Medical worth $8,752,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after buying an additional 435 shares during the last quarter. KBC Group NV increased its stake in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in shares of Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares during the period. Institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Performance

NARI stock opened at $51.55 on Wednesday. The stock’s 50 day simple moving average is $46.67 and its 200 day simple moving average is $47.62. The company has a market cap of $3.02 billion, a P/E ratio of -38.18 and a beta of 0.97. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $67.13.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NARI. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a “buy” rating and a $68.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Canaccord Genuity Group increased their price target on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Stifel Nicolaus assumed coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective on the stock. Finally, Leerink Partners started coverage on Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price for the company. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $58.89.

Insider Transactions at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now owns 445,310 shares in the company, valued at $22,265,500. This trade represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now owns 601,233 shares of the company’s stock, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 186,000 shares of company stock valued at $8,990,990 over the last ninety days. 10.60% of the stock is owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.